Insider Selling: Cryoport, Inc. (NASDAQ:CYRX) CEO Sells 2,980 Shares of Stock

Cryoport, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton sold 2,980 shares of the stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $6.94, for a total value of $20,681.20. Following the completion of the transaction, the chief executive officer now directly owns 762,419 shares in the company, valued at approximately $5,291,187.86. This represents a 0.39 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Jerrell Shelton also recently made the following trade(s):

• On Monday, March 17th, Jerrell Shelton sold 4,620 shares of Cryoport stock. The stock was sold at an average price of $6.29, for a total transaction of $29,059.80.
• On Monday, March 10th, Jerrell Shelton sold 4,173 shares of Cryoport stock. The shares were sold at an average price of $4.88, for a total transaction of $20,364.24.

Cryoport Trading Down 2.4 %

Shares of CYRX stock opened at $6.09 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. The stock has a fifty day simple moving average of $6.68 and a two-hundred day simple moving average of $7.32. The firm has a market capitalization of $303.95 million, a PE ratio of -1.80 and a beta of 1.67. Cryoport, Inc. has a 52-week low of $4.58 and a 52-week high of $20.11.

Cryoport (NASDAQ:CYRX) last released its earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.09). Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. The business had revenue of $59.53 million for the quarter, compared to analysts’ expectations of $58.71 million. During the same quarter in the prior year, the business posted ($0.29) EPS. On average, analysts predict that Cryoport, Inc. will post -0.99 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on CYRX shares. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Cryoport in a research note on Wednesday, March 5th. Guggenheim assumed coverage on Cryoport in a report on Thursday, December 19th. They set a “buy” rating and a $11.00 price target for the company. Finally, UBS Group raised Cryoport from a “neutral” rating to a “buy” rating and set a $10.00 price objective on the stock in a research note on Monday, March 24th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $11.67.

Institutional Investors Weigh In On Cryoport

Several institutional investors and hedge funds have recently modified their holdings of CYRX. Cadian Capital Management LP grew its stake in Cryoport by 14.1% during the fourth quarter. Cadian Capital Management LP now owns 4,927,027 shares of the company’s stock valued at $38,332,000 after acquiring an additional 609,021 shares in the last quarter. Millennium Management LLC grew its position in shares of Cryoport by 11.0% during the fourth quarter. Millennium Management LLC now owns 4,139,869 shares of the company’s stock valued at $32,208,000 after purchasing an additional 409,353 shares in the last quarter. Fred Alger Management LLC increased its holdings in shares of Cryoport by 49.9% in the third quarter. Fred Alger Management LLC now owns 2,698,768 shares of the company’s stock worth $21,887,000 after purchasing an additional 898,481 shares during the last quarter. Thematics Asset Management lifted its position in shares of Cryoport by 176.2% in the third quarter. Thematics Asset Management now owns 1,705,000 shares of the company’s stock worth $13,828,000 after buying an additional 1,087,800 shares in the last quarter. Finally, Deutsche Bank AG boosted its stake in Cryoport by 0.9% during the fourth quarter. Deutsche Bank AG now owns 1,397,121 shares of the company’s stock valued at $10,870,000 after buying an additional 12,864 shares during the last quarter. Institutional investors own 92.90% of the company’s stock.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.